glp-1/glucagon dual receptor agonist PDB-101: Molecule of the Month: GLP-1 Agonists Frontiers | GLP-1 Receptor Agonists:

But when they apply for life insurance, they're running into an unexpected problem: underwriters are treating their dramatic weight loss as a red flag, not a health victory

What Is GLP1 and Why Does It Matter

A large systemic review of cardiovascular outcomes of people taking GLP-1 agonists significantly reduces death from cardiovascular causes by 12% and stroke by 16%

The study discovered that over 40,000 of the 70,000+ participants taking a GLP-1 drug, like Ozempic, quit within one year, and 42% of the participants stopped within nine months

Lower GLP-1 drug prices are coming, but employers still need a sustainable cost strategy The Wondr Health Team As conversations about lowering GLP1 costs continue to dominate the benefits landscape, optimism is growing